MedTrace Logo

A Study to Evaluate AP-101 in Familial and Sporadic Amyotrophic Lateral Sclerosis (ALS)

NCT03981536 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2020-10-27

No results posted yet for this study

Summary

Single ascending doses of AP-101 will be administered by intravenous (IV) infusion

Conditions

Interventions

DRUG

AP-101

Administered by intravenous infusion (IV)

Sponsors & Collaborators

  • AL-S Pharma

    lead INDUSTRY

Principal Investigators

  • Study Director · AL-S Pharma SA

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-10
Primary Completion
2020-11-02
Completion
2020-11-02

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03981536 on ClinicalTrials.gov